Inoviem provides breakthrough protein technologies for each phase of the drug development process.
One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy
How to best identify the Mode of Action of your compound
From preclinical to clinical
Ensure Phase II study and success of your drug candidate in Phase III
Successfully identify the cohort of patients who will respond to your therapy